Figure 10.
(a) Stability of PEGylated CPT-P(Phe-OCA25) and PEGylated CPT-PLA25 nanoparticles in human serum buffer. (b) Intensity of Nile Red versus concentration of PEG5k-P(Phe-OCA100) and PEG5k-PLA100, and CMC determination (CMC = 2.2 × 10–2 mg·mL–1 and 4.5 × 10–2 mg·mL–1, respectively). (c) Particle size variation of PEGylated P(Phe-OCA100) and PEGylated PLA100 nanoparticles with or without dilution determined by DLS. Adapted with permissions from ref (54).